Asensus Surgical Inc. (AMEX:ASXC) has a beta value of 1.47 and has seen 1.67 million shares traded in the last trading session. The company, currently valued at $161.97M, closed the last trade at $0.68 per share which meant it gained $0.01 on the day or 0.73% during that session. The ASXC stock price is -36.76% off its 52-week high price of $0.93 and 58.82% above the 52-week low of $0.28. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.97 million shares traded. The 3-month trading volume is 1.01 million shares.
The consensus among analysts is that Asensus Surgical Inc. (ASXC) is a Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.07.
Asensus Surgical Inc. (AMEX:ASXC) trade information
Sporting 0.73% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, 01/23/23 when the ASXC stock price touched $0.68 or saw a rise of 7.68%. Year-to-date, Asensus Surgical Inc. shares have moved 95.76%, while the 5-day performance has seen it change 13.25%. Over the past 30 days, the shares of Asensus Surgical Inc. (AMEX:ASXC) have changed 101.63%. Short interest in the company has seen 9.8 million shares shorted with days to cover at 11.58.
Wall Street analysts have a consensus price target for the stock at $2.25, which means that the shares’ value could jump 69.78% from current levels. The projected low price target is $1.50 while the price target rests at a high of $3.00. In that case, then, we find that the current price level is -341.18% off the targeted high while a plunge would see the stock gain -120.59% from current levels.
Asensus Surgical Inc. (ASXC) estimates and forecasts
Figures show that Asensus Surgical Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained 37.77% over the past 6 months, with this year growth rate of -37.50%, compared to 1.10% for the industry. Revenue growth from the last financial year stood is estimated to be 11.20%.
2 analysts offering their estimates for the company have set an average revenue estimate of $2.9 million for the current quarter. 2 have an estimated revenue figure of $4.2 million for the next quarter concluding in Dec 2022. Year-ago sales stood $1.02 million and $2.48 million respectively for this quarter and the next, and analysts expect sales will grow by 184.30% for the current quarter and 69.60% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 54.40% over the past 5 years.
Asensus Surgical Inc. is expected to release its next earnings report between February 27 and March 03 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Asensus Surgical Inc. (AMEX:ASXC)’s Major holders
Insiders own 1.04% of the company shares, while shares held by institutions stand at 13.34% with a share float percentage of 13.48%. Investors are also buoyed by the number of investors in a company, with Asensus Surgical Inc. having a total of 110 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 10.86 million shares worth more than $4.32 million. As of Jun 29, 2022, Vanguard Group, Inc. (The) held 4.59% of shares outstanding.
The other major institutional holder is Millennium Management Llc, with the holding of over 5.04 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $2.01 million and represent 2.13% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Jun 29, 2022, the former fund manager holds about 3.10% shares in the company for having 7.34 million shares of worth $2.92 million while later fund manager owns 3.06 million shares of worth $1.22 million as of Jun 29, 2022, which makes it owner of about 1.29% of company’s outstanding stock.